{"id":"peginterferon-alfa-2a-ribavirin-epoetin","safety":{"commonSideEffects":[{"rate":null,"effect":"Anemia"},{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"40-60","effect":"Headache"},{"rate":"30-50","effect":"Nausea"},{"rate":"20-40","effect":"Neutropenia"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Depression/mood changes"},{"rate":"20-40","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peginterferon alfa-2a is an interferon that activates innate and adaptive immune responses to suppress viral replication. Ribavirin is a nucleoside analog that inhibits viral RNA synthesis. Epoetin-β (erythropoietin) stimulates red blood cell production to manage anemia caused by the antiviral agents.","oneSentence":"This combination therapy enhances immune response against hepatitis C virus while supporting red blood cell production to counteract treatment-induced anemia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:52.550Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype-dependent)"},{"name":"Hepatitis C with compensated cirrhosis"}]},"trialDetails":[{"nctId":"NCT00470210","phase":"PHASE4","title":"Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2007-05","conditions":"Hepatitis C, HIV Infections","enrollment":10},{"nctId":"NCT00356486","phase":"PHASE4","title":"Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-10","conditions":"HIV Infections","enrollment":74},{"nctId":"NCT00830609","phase":"PHASE4","title":"High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3","status":"COMPLETED","sponsor":"Dr. Conrado Fernandez","startDate":"2008-11","conditions":"Chronic Hepatitis C","enrollment":101},{"nctId":"NCT00526448","phase":"PHASE4","title":"Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients","status":"UNKNOWN","sponsor":"Hospital Carlos III, Madrid","startDate":"2007-06","conditions":"Chronic Hepatitis C","enrollment":384}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Peginterferon alfa-2a, Ribavirin, epoetin-β","genericName":"Peginterferon alfa-2a, Ribavirin, epoetin-β","companyName":"Germans Trias i Pujol Hospital","companyId":"germans-trias-i-pujol-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy enhances immune response against hepatitis C virus while supporting red blood cell production to counteract treatment-induced anemia. Used for Chronic hepatitis C virus infection (genotype-dependent), Hepatitis C with compensated cirrhosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}